It does matter, but I expressed in the post prior that the work has shown Leronlimab to be safe and effective, but they withdrew bla resubmission because it would fail based on shoddy data records.

But, it does matter none the less. Leronlimabs safety profile resides in that data, but it was aggregated and compiled and it stands, but it does not meet BLA resubmission quality.